Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Evercore ISI lowered the firm’s price target on Moderna (MRNA) to $50 from $60 and keeps an In Line rating on the shares. The firm is updating ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Moderna’s vaccine is designed to target H5 and H7 avian influenza viruses. The company plans to move into phase 3 clinical trials to test the vaccine in a larger group of people after receiving ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) was the target of unusually large options trading on Wednesday. Stock investors purchased 128,988 call options on the stock. This is an increase of ...

They set a “market perform” rating and a $55.00 target price ... and infectious diseases vaccines, such as lyme and norovirus vaccines. Receive News & Ratings for Moderna Daily - Enter your ...

The S&P 500 fell 0.5% on Wednesday, Jan. 29, as the Federal Reserve held interest rates steady in a move widely expected by ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

Moderna (NASDAQ: MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy. The downgrade follows a series of negative revisions to ...